Corwave

CorWave develops implantable left ventricular assist devices (LVADs), heart-assist pumps built on its wave membrane technology, which the company says produces truly pulsatile blood flow. Its products shown on the website are the LVAS and Nemo. The company describes itself as clinical-stage, and it announced the first implantation of its Left Ventricular System in a patient in 2025.

The stated customers are healthcare professionals treating advanced heart failure and the patients who receive these devices. The input does not describe the revenue model or pricing in detail; the company presents itself as a medical device company.

CorWave was incorporated in 2012 by the startup studio MD Start and is headquartered in Clichy, France, where it opened an urban factory in 2023. The website states it has more than 90 employees and has raised more than 80 million euros, including a Series C second closing of 61 million euros in 2023. Its open positions are in Clichy and cover manufacturing, quality, embedded software R&D and support functions.

Product: Implantable left ventricular assist devices (LVAS, Nemo) using wave membrane pump technology for advanced heart failure.